Ocular Therapeutix (OCUL) Cash from Financing Activities (2013 - 2026)

Ocular Therapeutix's Cash from Financing Activities history runs 14 years deep, the most recent figure standing at $294000.0 for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 92.97% year-over-year to $294000.0 in Q1 2026; TTM through Mar 2026 was $557.8 million, a 3601.61% increase from a year earlier, with the FY2025 full-year figure at $561.7 million, up 69.14% from the prior year.
• Cash from Financing Activities eased to $294000.0 in Q1 2026 per OCUL's latest filing, from $449.4 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $449.4 million in Q4 2025 and bottomed at $78000.0 in Q1 2023.
• The 5-year median for Cash from Financing Activities is $4.2 million (2025), against an average of $62.7 million.
• Across the five-year window, Cash from Financing Activities surged 411724.36% in 2024 and sank 98.7% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $458000.0 in 2022, then jumped by 23517.9% to $108.2 million in 2023, then tumbled by 95.83% to $4.5 million in 2024, then soared by 9857.37% to $449.4 million in 2025, then plunged by 99.93% to $294000.0 in 2026.
• Per Business Quant, the three latest OCUL Cash from Financing Activities figures stand at $294000.0 (Q1 2026), $449.4 million (Q4 2025), and $10.4 million (Q3 2025).